Poxel S.A.
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the tr… Read more
Poxel S.A. (0RA2) - Net Assets
Latest net assets as of June 2025: €-61.40 Million EUR
Based on the latest financial reports, Poxel S.A. (0RA2) has net assets worth €-61.40 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€5.00 Million) and total liabilities (€66.41 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-61.40 Million |
| % of Total Assets | -1227.83% |
| Annual Growth Rate | N/A |
| 5-Year Change | -319.27% |
| 10-Year Change | -254.98% |
| Growth Volatility | 1924.53 |
Poxel S.A. - Net Assets Trend (2010–2024)
This chart illustrates how Poxel S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Poxel S.A. (2010–2024)
The table below shows the annual net assets of Poxel S.A. from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-58.94 Million | -20.09% |
| 2023-12-31 | €-49.08 Million | -169.05% |
| 2022-12-31 | €-18.24 Million | -322.29% |
| 2021-12-31 | €8.21 Million | -69.47% |
| 2020-12-31 | €26.88 Million | -31.33% |
| 2019-12-31 | €39.14 Million | -29.83% |
| 2018-12-31 | €55.78 Million | +188.62% |
| 2017-12-31 | €19.33 Million | -50.93% |
| 2016-12-31 | €39.39 Million | +3.57% |
| 2015-12-31 | €38.03 Million | +1592.75% |
| 2014-12-31 | €-2.55 Million | +87.27% |
| 2013-12-31 | €-20.01 Million | -6451.85% |
| 2012-12-31 | €315.03K | -95.71% |
| 2011-12-31 | €7.35 Million | -30.56% |
| 2010-12-31 | €10.58 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Poxel S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 141910400.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €1.07 Million | % |
| Other Comprehensive Income | €-99.18 Million | % |
| Other Components | €39.17 Million | % |
| Total Equity | €-58.94 Million | 100.00% |
Poxel S.A. Competitors by Market Cap
The table below lists competitors of Poxel S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hanoi Plastics JSC
VN:NHH
|
$10.12 Million |
|
Cocrystal Pharma Inc
NASDAQ:COCP
|
$10.12 Million |
|
Kavango Resources Plc
PINK:KVGOF
|
$10.13 Million |
|
Agripure Holdings Public Company Limited
BK:APURE
|
$10.13 Million |
|
Aurora Labs Ltd
AU:A3D
|
$10.12 Million |
|
Huayi Tencent Entertainment Company Limited
PINK:HUYTF
|
$10.11 Million |
|
FSBM Holdings Bhd
KLSE:9377
|
$10.11 Million |
|
LLORENTE + CUENCA EO -01
F:91P
|
$10.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Poxel S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -49,105,000 to -58,937,000, a change of -9,832,000.
- Net loss of 18,305,000 reduced equity.
- Other comprehensive income decreased equity by 18,259,999.
- Other factors increased equity by 26,732,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-18.30 Million | -31.06% |
| Other Comprehensive Income | €-18.26 Million | -30.98% |
| Other Changes | €26.73 Million | +45.36% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Poxel S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | €0.42 | €0.25 | x |
| 2012-12-31 | €0.02 | €0.25 | x |
| 2013-12-31 | €-1.14 | €0.25 | x |
| 2014-12-31 | €-0.14 | €0.25 | x |
| 2015-12-31 | €2.12 | €0.25 | x |
| 2016-12-31 | €1.87 | €0.25 | x |
| 2017-12-31 | €0.84 | €0.25 | x |
| 2018-12-31 | €2.25 | €0.25 | x |
| 2019-12-31 | €1.51 | €0.25 | x |
| 2020-12-31 | €0.98 | €0.25 | x |
| 2021-12-31 | €0.29 | €0.25 | x |
| 2022-12-31 | €-0.63 | €0.25 | x |
| 2023-12-31 | €-1.27 | €0.25 | x |
| 2024-12-31 | €-1.23 | €0.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Poxel S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -275.84%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-217.42%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -117.37% | 0.00% | 0.00x | 1.38x | €-9.36 Million |
| 2012 | -2265.92% | 0.00% | 0.00x | 25.98x | €-7.17 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | €-18.45 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | €-13.83 Million |
| 2015 | -32.19% | -20521.40% | 0.00x | 1.23x | €-16.04 Million |
| 2016 | -62.16% | -34843.71% | 0.00x | 1.28x | €-28.42 Million |
| 2017 | -117.42% | -428.99% | 0.08x | 3.45x | €-24.63 Million |
| 2018 | 24.25% | 18.13% | 0.71x | 1.89x | €7.95 Million |
| 2019 | -65.77% | -96.93% | 0.37x | 1.85x | €-29.66 Million |
| 2020 | -117.71% | -468.09% | 0.10x | 2.40x | €-34.56 Million |
| 2021 | -289.57% | -177.37% | 0.24x | 6.69x | €-24.58 Million |
| 2022 | 0.00% | -4658.46% | 0.02x | 0.00x | €-29.57 Million |
| 2023 | 0.00% | -1771.33% | 0.41x | 0.00x | €-30.18 Million |
| 2024 | 0.00% | -275.84% | 0.44x | 0.00x | €-12.41 Million |
Industry Comparison
This section compares Poxel S.A.'s net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Poxel S.A. (0RA2) | €-61.40 Million | -117.37% | N/A | $10.12 Million |
| Nyfosa AB (0A0K) | $2.92 Billion | 39.50% | 2.88x | $973.31 Million |
| High Templar Tech Limited (0A2T) | $12.52 Billion | 4.70% | 0.13x | $255.82 Million |
| Strategy Inc (0A7O) | $51.04 Billion | -7.54% | 0.21x | $40.17 Billion |
| NACON SASU (0A9N) | $67.54 Million | 15.85% | 1.20x | $7.64 Million |
| Antin Infrastructure Partners (0AA5) | $23.79 Million | 108.98% | 1.09x | $573.10 Million |
| Truecaller AB Series B (0AA7) | $1.41 Billion | 18.30% | 0.20x | $281.60 Million |
| Brockhaus Technologies AG (0AAW) | $254.92 Million | -6.23% | 1.68x | $74.40 Million |
| Hyloris Pharmaceuticals S.A. (0AB6) | $48.06 Million | -24.09% | 0.32x | $71.96 Million |
| Kalray S.A. (0ABT) | $28.43 Million | -41.56% | 0.67x | $33.84 Million |
| Webuild S.p.A. (0BJP) | $1.43 Billion | 10.29% | 7.14x | $1.13 Billion |